Analyst Downgrades: Bed Bath & Beyond Inc., Valeant Pharmaceuticals Intl Inc, and Tesla Motors Inc

Analysts downwardly revised their ratings and price targets on Bed Bath & Beyond Inc. (NASDAQ:BBBY), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and Tesla Motors Inc (NASDAQ:TSLA)

by Josh Selway

Published on Jun 23, 2016 at 9:06 AM
Updated on Jun 24, 2020 at 10:16 AM

Analysts are weighing in on home goods retailer Bed Bath & Beyond Inc. (NASDAQ:BBBY), biotech stock Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and automaker Tesla Motors Inc (NASDAQ:TSLA). Here's a quick roundup of today's bearish brokerage notes on BBBY, VRX, and TSLA.

  • BBBY is down almost 4% in pre-market trading, following the company's disappointing first-quarter earnings release. This was met with a round of bearish analyst attention, including price-target cuts from no fewer than eight brokerage firms. Among the bunch was Credit Suisse, setting the lowest mark at $41. Bearish analyst attention is nothing new for Bed Bath & Beyond Inc., though. Just one of the 16 analysts providing coverage on the stock recommends buying it. And it's no wonder, considering BBBY has fallen almost 39% in the past 12 months, to trade at $43.18. 

  • VRX is edging 1.1% higher ahead of the open, despite a downgrade to "neutral" from "overweight" at J.P. Morgan Securities, which also cut its price target to $35 from $50. The stock closed Wednesday at $21.64, rebounding slightly after hitting fresh multi-year lows earlier this week. Despite its technical struggles, Valeant Pharmaceuticals Intl Inc bulls can still be found on Wall Street and in the options pits. For instance, five analysts still consider the stock a "strong buy," while VRX's Schaeffer's put/call open interest ratio (SOIR) of 0.63 marks a 12-month call-skewed low. 
  • TSLA looks poised to continue Wednesday's sell-off, as analysts turn bearish following the company's "no brainer" M&A announcement. Just this morning, Morgan Stanley downgraded the stock to "equal weight," while Berenberg lowered its price target to $145 from $150. While this is far below Tesla Motors Inc's Wednesday settlement at $196.66, the stock was trading below $145 as recently as February. Another day in the red could put TSLA in oversold territory, with the stock's 14-day Relative Strength Index (RSI) registering at 31 as of yesterday's close -- right above the oversold threshold. 
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter